



Mouse Anti-Ipilimumab monoclonal antibody, clone 5I7 [Biotin] (CABT-ZB211)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB211 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ipilimumab.
Specificity	The product is specific for Ipilimumab.
Target	Ipilimumab
Immunogen	Ipilimumab
Isotype	IgG1
Source/Host	Mouse
Clone	5I7
Purification	Protein A purified
Conjugate	Biotin
Applications	<p>ELISA(det), PK study</p> <p>Recommended Working Concentration:</p> <p>0.01-0.1 µg/ml</p> <p>We recommend the following for sandwich ELISA (Capture - Detection):</p> <p>CABT-ZB209 - CABT-ZB210; CABT-ZB209 - CABT-ZB211</p> <p>The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody CABT-ZB209.</p>
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.

Size	40 µg
Buffer	Lyophilized with PBS, pH 7.4, contains 1% BSA and 0.02% sodium azide.
Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells.
Keywords	Mouse monoclonal antibody to Yervoy; Anti-CTLA4; Ipilimumab; MDX 010

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Yervoy; Anti-CTLA4; Ipilimumab; MDX 010
-----------------	--